1068607-13-5 Usage
General Description
N-(2-(2-chloro-5-nitropyrimidin-4-ylamino)ethyl)acetamide is a chemical compound with the molecular formula C9H10ClN5O3. It is a derivative of acetamide and contains a nitro group, a chloro group, and a pyrimidine ring. N-(2-(2-chloro-5-nitropyrimidin-4-ylamino)ethyl)acetamide is commonly used in the pharmaceutical industry as a building block for the synthesis of various drugs. It has also shown potential as an antifungal agent and is being studied for its potential pharmacological properties. Additionally, it can be used in organic synthesis for the preparation of various heterocyclic compounds. Due to its structure and properties, N-(2-(2-chloro-5-nitropyrimidin-4-ylamino)ethyl)acetamide has a wide range of potential applications in both pharmaceutical and chemical industries.
Check Digit Verification of cas no
The CAS Registry Mumber 1068607-13-5 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,6,8,6,0 and 7 respectively; the second part has 2 digits, 1 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 1068607-13:
(9*1)+(8*0)+(7*6)+(6*8)+(5*6)+(4*0)+(3*7)+(2*1)+(1*3)=155
155 % 10 = 5
So 1068607-13-5 is a valid CAS Registry Number.
1068607-13-5Relevant articles and documents
Novel, potent, selective, and metabolically stable stearoyl-CoA desaturase (SCD) inhibitors
Koltun, Dmitry O.,Parkhill, Eric Q.,Vasilevich, Natalya I.,Glushkov, Andrei I.,Zilbershtein, Timur M.,Ivanov, Alexei V.,Cole, Andrew G.,Henderson, Ian,Zautke, Nathan A.,Brunn, Sandra A.,Mollova, Nevena,Leung, Kwan,Chisholm, Jeffrey W.,Zablocki, Jeff
scheme or table, p. 2048 - 2052 (2009/11/30)
We identified a series of structurally novel SCD (Δ9 desaturase) inhibitors via high-throughput screening and follow-up SAR studies. Modification of the central bicyclic scaffold has proven key to our potency optimization effort. The most potent analog (8
Pyrimidine derivatives
-
, (2011/04/19)
The present invention relates to trisubstituted pyrimidines of formula (I) 1wherein 0Ra to Re are defined as in claim 1, which are suitable for the treatment of illnesses characterised by excessive or abnormal cell proliferation, the use thereof for preparing a pharmaceutical composition with the abovementioned properties, and processes for the preparation thereof.